Arellano ML et al. Menin inhibition with revumenib for NPM1-mutated relapsed or refractory acute myeloid leukemia: The AUGMENT-101 study. Blood 2025;[Online ahead of print]. Abstract
Issa GC et al. Menin inhibition with revumenib for KMT2A-rearranged relapsed or refractory acute leukemia (AUGMENT-101). J Clin Oncol 2025;43(1):75-84. Abstract
Issa GC et al. Clinical outcomes associated with NPM1 mutations in patients with relapsed or refractory AML. Blood Adv 2023;7(6):933-42. Abstract
Issa GC et al. The menin inhibitor revumenib in KMT2A-rearranged or NPM1-mutant leukaemia. Nature 2023;615(7954):920-4. Abstract
Mahdavi L et al. Clonal evolution mediates menin-inhibitor resistance in KMT2A-rearranged leukemias. bioRxiv 2023. Abstract
Perner F et al. MEN1 mutations mediate clinical resistance to menin inhibition. Nature 2023;615:913-9. Abstract
Soto-Feliciano YM et al. A molecular switch between mammalian MLL complexes dictates response to menin-MLL inhibition. Cancer Discov 2023;13(1):146-69. Abstract
Wang ES et al. Ziftomenib in relapsed/refractory (R/R) NPM1-mutant acute myeloid leukemia (AML): Phase 1b/2 clinical activity and safety results from the pivotal KOMET-001 study. ASCO 2025;Abstract 6506
Wang ES et al. Ziftomenib in relapsed or refractory acute myeloid leukaemia (KOMET-001): A multicentre, open-label, multi-cohort, phase 1 trial. Lancet Oncol 2024;25:1310-24. Abstract